vs

Side-by-side financial comparison of HARTE HANKS INC (HHS) and TREACE MEDICAL CONCEPTS, INC. (TMCI). Click either name above to swap in a different company.

TREACE MEDICAL CONCEPTS, INC. is the larger business by last-quarter revenue ($62.5M vs $39.9M, roughly 1.6× HARTE HANKS INC). HARTE HANKS INC runs the higher net margin — 5.5% vs -15.0%, a 20.6% gap on every dollar of revenue. On growth, TREACE MEDICAL CONCEPTS, INC. posted the faster year-over-year revenue change (-9.0% vs -15.4%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-10.4M). Over the past eight quarters, TREACE MEDICAL CONCEPTS, INC.'s revenue compounded faster (10.6% CAGR vs -6.4%).

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

HHS vs TMCI — Head-to-Head

Bigger by revenue
TMCI
TMCI
1.6× larger
TMCI
$62.5M
$39.9M
HHS
Growing faster (revenue YoY)
TMCI
TMCI
+6.4% gap
TMCI
-9.0%
-15.4%
HHS
Higher net margin
HHS
HHS
20.6% more per $
HHS
5.5%
-15.0%
TMCI
More free cash flow
HHS
HHS
$9.7M more FCF
HHS
$-686.0K
$-10.4M
TMCI
Faster 2-yr revenue CAGR
TMCI
TMCI
Annualised
TMCI
10.6%
-6.4%
HHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HHS
HHS
TMCI
TMCI
Revenue
$39.9M
$62.5M
Net Profit
$2.2M
$-9.4M
Gross Margin
80.6%
Operating Margin
-0.3%
-9.5%
Net Margin
5.5%
-15.0%
Revenue YoY
-15.4%
-9.0%
Net Profit YoY
-1775.0%
EPS (diluted)
$0.30
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HHS
HHS
TMCI
TMCI
Q4 25
$39.9M
$62.5M
Q3 25
$39.5M
$50.2M
Q2 25
$38.6M
$47.4M
Q1 25
$41.6M
$52.6M
Q4 24
$47.1M
$68.7M
Q3 24
$47.6M
$45.1M
Q2 24
$45.0M
$44.5M
Q1 24
$45.4M
$51.1M
Net Profit
HHS
HHS
TMCI
TMCI
Q4 25
$2.2M
$-9.4M
Q3 25
$-2.3M
$-16.3M
Q2 25
$-335.0K
$-17.4M
Q1 25
$-392.0K
$-15.9M
Q4 24
$-501.0K
Q3 24
$142.0K
$-15.4M
Q2 24
$-27.8M
$-21.2M
Q1 24
$-171.0K
$-18.7M
Gross Margin
HHS
HHS
TMCI
TMCI
Q4 25
80.6%
Q3 25
79.1%
Q2 25
79.7%
Q1 25
79.7%
Q4 24
80.7%
Q3 24
80.1%
Q2 24
80.2%
Q1 24
80.2%
Operating Margin
HHS
HHS
TMCI
TMCI
Q4 25
-0.3%
-9.5%
Q3 25
1.3%
-31.2%
Q2 25
0.1%
-35.8%
Q1 25
-0.1%
-29.6%
Q4 24
-3.3%
-0.3%
Q3 24
4.0%
-33.6%
Q2 24
3.0%
-48.1%
Q1 24
0.8%
-37.1%
Net Margin
HHS
HHS
TMCI
TMCI
Q4 25
5.5%
-15.0%
Q3 25
-5.8%
-32.4%
Q2 25
-0.9%
-36.7%
Q1 25
-0.9%
-30.3%
Q4 24
-0.7%
Q3 24
0.3%
-34.1%
Q2 24
-61.8%
-47.7%
Q1 24
-0.4%
-36.5%
EPS (diluted)
HHS
HHS
TMCI
TMCI
Q4 25
$0.30
$-0.14
Q3 25
$-0.31
$-0.26
Q2 25
$-0.05
$-0.28
Q1 25
$-0.05
$-0.25
Q4 24
$-0.31
$-0.01
Q3 24
$0.02
$-0.25
Q2 24
$-3.84
$-0.34
Q1 24
$-0.02
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HHS
HHS
TMCI
TMCI
Cash + ST InvestmentsLiquidity on hand
$5.6M
$48.4M
Total DebtLower is stronger
$55.6M
Stockholders' EquityBook value
$20.5M
$87.3M
Total Assets
$91.8M
$190.6M
Debt / EquityLower = less leverage
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HHS
HHS
TMCI
TMCI
Q4 25
$5.6M
$48.4M
Q3 25
$6.5M
$57.4M
Q2 25
$4.8M
$69.3M
Q1 25
$9.0M
$76.1M
Q4 24
$9.8M
$75.7M
Q3 24
$5.9M
$82.8M
Q2 24
$11.0M
$95.0M
Q1 24
$11.5M
$110.0M
Total Debt
HHS
HHS
TMCI
TMCI
Q4 25
$55.6M
Q3 25
$53.5M
Q2 25
$53.5M
Q1 25
$53.4M
Q4 24
$53.3M
Q3 24
$53.2M
Q2 24
$53.2M
Q1 24
$53.1M
Stockholders' Equity
HHS
HHS
TMCI
TMCI
Q4 25
$20.5M
$87.3M
Q3 25
$19.9M
$89.2M
Q2 25
$22.2M
$97.6M
Q1 25
$21.4M
$105.3M
Q4 24
$21.7M
$112.9M
Q3 24
$21.0M
$104.9M
Q2 24
$20.6M
$112.1M
Q1 24
$20.0M
$126.4M
Total Assets
HHS
HHS
TMCI
TMCI
Q4 25
$91.8M
$190.6M
Q3 25
$92.7M
$196.6M
Q2 25
$95.0M
$206.4M
Q1 25
$100.6M
$205.8M
Q4 24
$101.8M
$217.1M
Q3 24
$108.1M
$212.9M
Q2 24
$109.7M
$226.1M
Q1 24
$113.4M
$242.7M
Debt / Equity
HHS
HHS
TMCI
TMCI
Q4 25
0.64×
Q3 25
0.60×
Q2 25
0.55×
Q1 25
0.51×
Q4 24
0.47×
Q3 24
0.51×
Q2 24
0.47×
Q1 24
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HHS
HHS
TMCI
TMCI
Operating Cash FlowLast quarter
$737.0K
$-8.0M
Free Cash FlowOCF − Capex
$-686.0K
$-10.4M
FCF MarginFCF / Revenue
-1.7%
-16.7%
Capex IntensityCapex / Revenue
3.6%
3.8%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-4.5M
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HHS
HHS
TMCI
TMCI
Q4 25
$737.0K
$-8.0M
Q3 25
$3.2M
$-9.1M
Q2 25
$-4.8M
$-3.0M
Q1 25
$-818.0K
$4.2M
Q4 24
$4.0M
$-4.2M
Q3 24
$-2.9M
$-11.8M
Q2 24
$1.6M
$-13.9M
Q1 24
$-5.7M
$-7.2M
Free Cash Flow
HHS
HHS
TMCI
TMCI
Q4 25
$-686.0K
$-10.4M
Q3 25
$2.2M
$-11.9M
Q2 25
$-5.1M
$-7.8M
Q1 25
$-923.0K
$655.0K
Q4 24
$3.4M
$-7.3M
Q3 24
$-4.9M
$-14.7M
Q2 24
$926.0K
$-15.6M
Q1 24
$-6.2M
$-11.1M
FCF Margin
HHS
HHS
TMCI
TMCI
Q4 25
-1.7%
-16.7%
Q3 25
5.5%
-23.7%
Q2 25
-13.1%
-16.5%
Q1 25
-2.2%
1.2%
Q4 24
7.3%
-10.6%
Q3 24
-10.2%
-32.6%
Q2 24
2.1%
-35.2%
Q1 24
-13.7%
-21.8%
Capex Intensity
HHS
HHS
TMCI
TMCI
Q4 25
3.6%
3.8%
Q3 25
2.5%
5.6%
Q2 25
0.6%
10.1%
Q1 25
0.3%
6.7%
Q4 24
1.3%
4.5%
Q3 24
4.0%
6.4%
Q2 24
1.5%
3.9%
Q1 24
1.2%
7.7%
Cash Conversion
HHS
HHS
TMCI
TMCI
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-20.76×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

TMCI
TMCI

Segment breakdown not available.

Related Comparisons